YAP-Driven Malignant Reprogramming of Epithelial Stem Cells at Single Cell Resolution.
J Silvio Gutkind, Farhoud Faraji, Sydney Ramirez, Lauren Clubb, Kuniaki Sato, Paola Anguiano Quiroz, William Galloway, Zbigniew Mikulski, Thomas Hoang, Kate Medetgul-Ernar and 10 more
Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
Farhoud FarajiUniversity of California San Diego Health Department of Otolaryngology-Head and Neck Surgery and Moores Cancer Center.
Sydney RamirezLa Jolla Institute of Immunology.
Lauren ClubbUniversity of California San Diego Health Moores Cancer Center.
Kuniaki SatoUniversity of California San Diego Health Moores Cancer Center.
Paola Anguiano QuirozUniversity of California San Diego Health Moores Cancer Center.
William GallowayUniversity of California Irvine Department of Chemical and Biomolecular Engineering.
Zbigniew MikulskiLa Jolla Institute of Immunology.
Thomas HoangUniversity of California San Diego Health Moores Cancer Center.
Kate Medetgul-ErnarUniversity of California San Diego Health Moores Cancer Center.
Pauline MarangoniCraniofacial Biology and Department of Orofacial Sciences, University of California, San Francisco.
Kyle JonesUniversity of California San Francisco (UCSF).
Adam OfficerUniversity of California San Diego Health Moores Cancer Center.
Alfredo MolinoloUniversity of California San Diego Health Moores Cancer Center.
Kenneth KimLa Jolla Institute of Immunology.
Kanako SakaguchiIDEXX Laboratories KK.
Joseph CalifanoUniversity of California San Diego.
Quinton SmithUniversity of California Irvine Department of Chemical and Biomolecular Engineering.
Ophir KleinCedars-Sinai Medical Center, Los Angeles.
Pablo TamayoUniversity of California, San Diego.
UC San Diego Health System · USLa Jolla Institute for Immunology · USUniversity of California San Diego · USUniversity of California, Irvine · USUniversity of California, San Francisco · USCedars-Sinai Medical Center · USIDEXX Laboratories (France) · FR
Funding
VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
RESEARCH IN INFECTIOUS DISEASEST32AI007036 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NIZET, VICTOR · 1985 to 2025
$9.2M
Targeting Signaling Vulnerabilities for Oral Cancer PreventionR01DE026644 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jorge Silvio Gutkind, SCOTT M LIPPMAN · 2017 to 2026
$4.7M
Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck CancersU01DE028227 · NIDCR · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI GUTKIND, JORGE SILVIO, RAO, ANJANA · 2018 to 2022
$4.6M
Supporting and evolving Gene Set Enrichment Analysis and the Molecular Signatures Database for cancer researchU24CA220341 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P., TAMAYO, PABLO · 2018 to 2022
$3.4M
Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal MelanomaR01CA257505 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI APLIN, ANDREW ERIC, GUTKIND, JORGE SILVIO · 2021 to 2025
$2.7M
Signal Transduction by PI3K/mTORR01DE030497 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GUTKIND, JORGE SILVIO, ZHANG, JIN · 2021 to 2025
$2.4M
Targeting the EGFR-PI3K/mTOR Signaling Circuitry: A Network-Based Approach for Oral Cancer Precision TherapyR01DE026870 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GUTKIND, JORGE SILVIO · 2018 to 2022
$2.3M
OTOLARYNGOLOGY TRAINING IN IMMUN., VIROL. &MOLEC. BIOL.T32DC000028 · NIDCD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RYAN, ALLEN F. · 1989 to 2020
$2.1M
Multidisciplinary Educational Approach to Reducing Cancer DisparitiesR25CA221779 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GUTKIND, JORGE SILVIO, SADLER, GEORGIA ROBINS · 2019 to 2023
$2.1M
NovaSeq5000 High Throughput SequencerS10OD025052 · OD · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SEUMOIS, GREGORY · 2018 to 2018
$832k
FACSAria II Cell SorterS10RR027366 · NCRR · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROFT, MICHAEL · 2011 to 2011
Tumor initiation represents the first step in tumorigenesis during which normal progenitor cells undergo cell fate transition to cancer. Capturing this process as it occurs
Indexed as
Cancer stem cellHippo pathwayHNSCCHPVOral cancerSquamous cell carcinomaTumor initiating cellTumor initiationYAP
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
YAP-Driven Malignant Reprogramming of Epithelial Stem Cells at Single Cell Resolution. · full record | OpenQuestion